Intriguingly, after ex vivo infection of interleukin-4 (IL-4)/IL-13-treated skin, we observed infected cells supporting that Th2 responses already enabled the virus to overcome the protective skin barrier and gain access to its receptors to initiate infection. The gene discussed is IL13; the disease is infection.